Abdel-Salam OME, Khadrawy YA, Mohammed NA (2012) Neuroprotective effect of nitric oxide donor isosorbide-dinitrate against oxidative stress induced by ethidium bromide in rat brain. EXCLI J 11:125–141

Abdel-Salam OME, Youness ER, Mohammed NA, Abu Elhamed WA (2015) Nuclear factor-kappa B and other oxidative stress biomarkers in serum of autistic children. Open J Mol Integr Physiol 5:18–27

Abdel-Salam OME, Youness ER, Morsy FM, Mahfouz MM, Kenawy SA (2014) Study of the effect of antidepressant drugs and donepezil on aluminum-induced memory impairment and biochemical alterations in rats. Comp Clin Pathol. doi:10.1007/s00580-014-1994-7

Ahn HS, Crim W, Romano M, Sybertz E, Pitts B (1989) Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38:3331–3339

Aksu F, Gültekin I, Inan SY, Baysal F (1998) The effects of piracetam on morphine-induced amnesia and analgesia: the possible contribution of central opiatergic mechanisms on the antiamnestic effect of piracetam. Inflammopharmacology 6:53–65

Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25:335–358

Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414

Bhattacharya SK, Upadhyay SN, Jaiswal AK, Bhattacharya S (1989) Effect of piracetam, a nootropic agent, on rat brain monoamines and prostaglandins. Indian J Exp Biol 27:261–264

Boje KMK (2004) Nitric oxide neurotoxicity in neurodegenerative diseases. Front Biosci 9:763–776

Brigandi SA, Shao H, Qian SY, Shen Y, Wu BL, Kang JX (2015) Autistic children exhibit decreased levels of essential fatty acids in red blood cells. Int J Mol Sci 16:10061–10076

Budygin EA, Gaĭnetdinov RR, Titov DA, Kovalev GI (1996) The effect of a low dose of piracetam on the activity of the dopaminergic system in the rat striatum. Eksp Klin Farmakol 59:6–8, Article in Russian

Cai Y, Li JD, Yan C (2013) Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun 434:439–443

Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 111:503–509

Chopin P, Briley M (1992) Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology 106:26–30

Coyle JT, Price DL, De Long MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190

Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic Biol Med 44:1787–1794

Drago D, Folin M, Baiguera S, Tognon G, Ricchelli F, Zatta P (2007) Comparative effects of Abeta(1-42)-Al complex from rat and human amyloid on rat endothelial cell cultures. J Alzheimers Dis 11:33–44

Dringen R (2000) Metabolism and functions of glutathione in brain. Prog Neurobiol 62:649–671

Eckert GP, Cairns NJ, Muller WE (1999) Piracetam reverses hippocampal membrane alterations in Alzheimer’s disease. J Neural Transm 106:757–761

Ellman GL, Courtney KD, Andreas V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharm 7:88–90

Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem 82:70–77

Exley C (2004) The pro-oxidant activity of aluminum. Free Radic Biol Med 36:380–387

Bondy SC (2014) Prolonged exposure to low levels of aluminum leads to changes associated with brain aging and neurodegeneration. Toxicology 315:1–7

Esparza JL, Gomez M, Romeu M, Mulero M, Sanchez DJ, Mallol J, Domingo JL (2003) Aluminum-induced pro-oxidant effects in rats: protective role of exogenous melatonin. J Pineal Res 35:32–39

Fang Y, Qiu Z, Hu W, Yang J, Yi X, Huang L, Zhang S (2014) Effect of piracetam on the cognitive performance of patients undergoing coronary bypass surgery: a meta-analysis. Exp Ther Med 7:429–434

Fischhof PK, Möslinger-Gehmayr R, Herrmann WM, Friedmann A, Russmann DL (1996) Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 34:29–35

Förstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829–837, 837a–837d

Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147

Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47

Furlong CE (2008) Paraoxonases: an historical perspective. In: Mackness B, Mackness M, Aviram M, Paragh G (eds) The paraoxonases: their role in disease development and xenobiotic metabolism. Springer, Dordrecht, pp 3–31

Gabryel B, Adamek M, Pudełko A, Małecki A, Trzeciak HI (2002) Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 23:19–31

Giacobini E (2001) Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer’s disease? Drugs Aging 18:891–898

Giacobini E (2004) Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 50:433–440

Giurgea C (1973) The nootropic approach to the pharmacology of the integrative activity of the brain. Cond Reflex 8:108–115

Golub MS, Han B, Keen CL (1999) Aluminum uptake and effects on transferring mediated iron uptake in primary cultures of rat neurons, astrocytes and oligodendrocytes. Neurotoxicology 20:961–970

Gorun V, Proinov I, Baltescu V, Balaban G, Barzu O (1978) Modified Ellman procedure for assay of cholinesterases in crude enzymatic preparation. Anal Biochem 86:324–326

Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK (2001) A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17:159–165

Gulya K, Rakonczay Z, Kása P (1990) Cholinotoxic effects of aluminum in rat brain. J Artic J Neurochem 54:1020–1026

Gulyás B, Halldin C, Vas A, Banati RB, Shchukin E, Finnema S, Tarkainen J, Tihanyi K, Szilágyi G, Farde L (2005) [11C]vinpocetine: a prospective peripheral benzodiazepine receptor ligand for primate PET studies. J Neurol Sci 229–230:219–223

Gutteridge JM (1995) Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 41:1819–1828

Gutteridge JM, Quinlan GJ, Clark I, Halliwell B (1985) Aluminium salts accelerate peroxidation of membrane lipids stimulated byiron salts. Biochim Biophys Acta 835:441–447

Guix FX, Uribesalgo I, Coma M, Muñoz FJ (2005) The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76:126–152

Hadjiev D (2003) Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz 56:166–172

Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609–1623

Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685–716

Halliwell B, Gutteridge JM (eds) (1989) Free radicals in biology and medicine, 2nd ed. Clarendon Press, Oxford, pp 22–85

He Z, Hu M, Zha YH, Li ZC, Zhao B, Yu LL, Yu M, Qian Y (2014) Piracetam ameliorated oxygen and glucose deprivation-induced injury in rat cortical neurons via inhibition of oxidative stress, excitatory amino acids release and P53/Bax. Cell Mol Neurobiol 34:539–547

Heckman PR, Wouters C, Prickaerts J (2015) Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer’s disease: a translational overview. Curr Pharm Des 21:317–331

Hermida-Ameijeiras A, Méndez-Alvarez E, Sánchez-Iglesias S, Sanmartín-Suárez C, Soto-Otero R (2004) Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int 45:103–116

Higashino K, Takahashi Y, Yamamura Y (1972) Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta 41:313–320

Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain. Acta Neuropathol (Berl) 101:2–8

Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K (2002) In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 25:37–42

Jacewicz M, CzapskiGA KI, Strosznajder RP (2009) Systemic administration of lipopolysaccharide impairs glutathione redox state and object recognition in male mice. The effect of PARP-1 inhibitor. Folia Neuropathol 47:321–328

Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A 107:9795–9800

Jovanović ZB, Pavlović AM, Pekmezović T, Mijajlović M, Covicković NS (2013) Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study. Ideggyogy Sz 66:263–268

Kaizer RR, CorrÃªa MC, Gris LR, da Rosa CS, Bohrer D, Morsch VM, Schetinger MR (2008) Effect of long-term exposure to aluminum on the acetylcholinesterase activity in the central nervous system and erythrocytes. Neurochem Res 33:2294–2301

Kalkan E, Keskin F, Kaya B, Esen H, Tosun M, Kalkan SS, Erdi F, Unlü A, Avunduk MC, Cicek O (2011) Effects of iloprost and piracetam in spinal cord ischemia-reperfusion injury in the rabbit. Spinal Cord 49:81–86

Kawahara M (2005) Effects of aluminum on the nervous system and its possible link with neurodegenerative diseases. J Alzheimers Dis 8:171–182

Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WE (2006) Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 147:199–208

Kessler J, Thiel A, Karbe H, Heiss WD (2000) Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. Stroke 31:2112–2116

Kosasa T, Kuriya Y, Matsui K, Yamanishi Y (1999) Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 380:101–107

Kurz C, Ungerer I, Lipka U, Kirr S, Schütt T, Eckert A, Leuner K, Müller WE (2010) The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide. Br J Pharmacol 160:246–257

La Du BN (1992) Human serum paraoxonase: arylesterase. In: Kalow W (ed) Pharmacogenetics of drug metabolism. Pergamon Press, New York, pp 51–91

LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484–1491

Leclerc JL, Lampert AS, Diller MA, Immergluck JB, Doré S (2015) Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery. ASN Neuro 7: pii: 1759091415578713

Lévesque L, Mizzen CA, McLachlan DR, Fraser PE (2000) Ligand specific effects on aluminum incorporation and toxicity in neurons and astrocytes. Brain Res 877:191–202

Matsumura K, Kobayashi S (2004) Signaling the brain in inflammation: the role of endothelial cells. Front Biosci 9:2819–2826

McCord JM (2000) The evolution of free radicals and oxidative stress. Am J Med 108:652–659

Menini T, Gugliucci A (2013) Paraoxonase 1 in neurological disorders. Redox Rep 19:49–58

Miranda KM, Espey MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5:62–71

Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PG, Szombathelyi Z, Tihanyi K (2009) Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 15:89–99

Oláh VA, Balla G, Balla J, Szabolcs A, Karmazsin L (1990) An in vitro study of the hydroxyl scavenger effect of Cavinton. Acta Paediatr Hung 30:309–316

Pallavi S, Amar J, Singh R, Hussain E, Sharma D (2008) Aluminium induced electrophysiological, biochemical and cognitive modifications in the hippocampus of aging rats. Neurotoxicology 29:1069–1079

Perry VH, Cunningham C, Holmes C (2007) Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7:161–167

Pocchiari M, Levi G (2000) Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 59:866–871

Rajkovic MG, Rumora L, Barisic K (2011) The paraoxonase 1, 2 and 3 in humans. Biochem Med (Zagreb) 21:122–130

Rago LK, Allikmets LH, Zarkovsky AM (1981) Effects of piracetam on the central dopaminergic transmission. Naunyn-Schmiedeberg’s Arch Pharmacol 318:36–37

Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS et al (2000) Oxidative insults are associated with apolipoprotein E genotype in Alzheimer’s disease brain. Neurobiol Dis 7:23–37

Rojas A, Ganesh T, Lelutiu N, Gueorguieva P, Dingledine R (2015) Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus. Neuropharmacology 93:15–27

Roth AD, Ramírez G, Alarcón R, Von Bernhardi R (2005) Oligodendrocytes damage in Alzheimer’s disease: Beta amyloid toxicity and inflammation. Biol Res 38:381–387

Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H (1994) Antioxidant effects of estradiol and 2-hydroxyestradiol on iron induced lipid peroxidation of rat liver microsomes. Steroids 59:383–388

Sajdel-Sulkowska EM, Lipinski B, Windom B, Audhya T, McGinnis W (2008) Oxidative stress in Autism: elevated cerebellar 3-nitrotyrosine levels. Am J Biochem Biotechnol 4:73–84

Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355

Sies H (ed) (1991) Oxidative stress. Oxidants and antioxidants. Academic Press, New York

Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130

Stahlhut L, Grotemeyer KH, Husstedt IW, Evers S (2014) The impact of stroke on cognitive processing—a prospective event-related potential study. J Neurol Sci 339:157–163

Stancheva SL, Petkov VD, Hadjiivanova CI, Petkov VV (1991) Age-related changes of the effects of a group of nootropic drugs on the content of rat brain biogenic monoamines. Gen Pharmacol 22:873–877

Stevanović I, Jovanović M, Jelenković A, Bokonjić D, Čolić M, Stojanović I, Ninković M (2009) Effect of L-NAME on AlCl3-induced toxicity in rat brain. Acta Vet (Beograd) 59:133–146

Struys-Ponsar C, Kerkhofs A, Gauthier A, Soffié M, van den Bosch de Aguilar P (1997) Effects of aluminum exposure on behavioral parameters in the rat. Pharmacol Biochem Behav 56:643–648

Sugimoto H, Hiroo Ogura H, Arai Y, Iimura Y, Yamanishi Y (2002) Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Jpn J Pharmacol 89:7–20

Szilágyi G, Nagy Z, Balkay L, Boros I, Emri M, Lehel S, Márián T, Molnár T, Szakáll S, Trón L, Bereczki D, Csiba L, Fekete I, Kerényi L, Galuska L, Varga J, Bönöczk P, Vas A, Gulyás B (2005) Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. J Neurol Sci 229–230:275–284

Tárnok K, Kiss E, Luiten PG, Nyakas C, Tihanyi K, Schlett K, Eisel UL (2008) Effects of vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem Int 53:289–295

Trejo F, Nekrassov V, Sitges M (2001) Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res 909:59–67

Vasilache AM, Qian H, Blomqvist A (2015) Immune challenge by intraperitoneal administration of lipopolysaccharide directs gene expression in distinct blood–brain barrier cells toward enhanced prostaglandin E2 signaling. Brain Behav Immun pii: S0889-1591(15)00021-5

Waegemans T, Wilsher CR, Danniau A et al (2002) Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord 13:217–224

Walton JR (2007) An aluminum-based rat model for Alzheimer’s disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. Inorg Biochem 101:1275–1284

Walton JR, Wang MX (2009) APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease. J Inorg Biochem 103:1548–1554

Wang H, Ye M, Yu L, Wang J, Guo Y, Lei W, Yang J (2015) Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration. Behav Brain Funct 11:8

Warner DS, Sheng H, Batinic-Haberle I (2004) Oxidants, antioxidants and the ischemic brain. J Exp Biol 207:3221–3231

Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882–2891

Wehr H, Bednarska-Makaruk M, Graban A, Lipczyńska-Łojkowska W, Rodo M, Bochyńska A, Ryglewicz D (2009) Paraoxonase activity and dementia. J Neurol Sci 283:107–108

Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J (2004) Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 21:453–478

Winblad B (2005) Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 11:169–182

Yang WN, Han H, Hu XD, Feng GF, Qian YH (2013) The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress. Pharmacol Biochem Behav 114–115:31–36

Yuan CY, Lee YJ, Hsu GS (2012) Aluminum overload increases oxidative stress in four functional brain areas of neonatal rats. J Biomed Sci 19:5

Yumoto S, Kakimi S, Ohsaki A, Ishikawa A (2009) Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer’s disease. J Inorg Biochem 103:1579–1584

Zatta P, Ibn-Lkhayat-Idrissi M, Zambenedetti P, Kilyen M, Kiss T (2002) In vivo and in vitro effects of aluminum on the activity of mouse brain acetylcholinesterase. Brain Res Bull 59:41–45

Zhou X, Dong XW, Crona J, Maguire M, Priestley T (2003) Vinpocetine is a potent blocker of rat NaV1.8 tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 306:498–504